Background
==========

Herpes viruses are neurotropic and may cause encephalitis, a serious condition with mortality rates around 10-20% overall mortality and up to 20-30% for untreated Herpes simplex-1 (HSV-1) encephalitis. Therefore the detection of these viruses in patients with suspected viral infections of the central nervous system (CNS) is well studied \[[@B1]-[@B7]\]. Due to their neurotropism, alpha-herpesviridae may reside latently in neurons after the primary infection. Dormant viruses may subsequently reactivate and cause symptoms of meningoencephalitis. However, it is not known if viral particles are shed into the cerebrospinal fluid (CSF) during the latent phase, since few studies have investigated the presence of herpes viruses in the CSF of patients lacking symptoms of viral CNS infection \[[@B8],[@B9]\]. In an earlier study, Davies et al. showed that viral nucleic acid (NA) could be detected by PCR in 5% of patients classified as having a low probability of CNS infection \[[@B8]\].

Although PCR is a highly sensitive method for detection it may not always be sensitive enough for identification of viral DNA in CSF, due to the fact that viral shedding from latent infection may be very low. Multiple displacement amplification (MDA), a whole genome amplification (WGA) method for isothermal uniform amplification of total DNA, might serve to increase the sensitivity of the polymerase chain reaction (PCR)\[[@B10],[@B11]\]. To our knowledge only a few studies have used MDA in connection with viral detection \[[@B12]-[@B14]\].

The aims of this project were to investigate the possibility to detect viral nucleic acid in CSF from patients without clinical symptoms or signs of viral infection and if herpes- or enterovirus might cause symptoms mistaken for bacterial CNS infections. Attempts were made to increase the sensitivity by amplifying total DNA with MDA prior to real-time PCR.

Methods
=======

Patients
--------

Samples of CSF from 373 patients from Östergötland County were included in the study (Table [1](#T1){ref-type="table"}). No viral analysis had been performed on the majority of these samples. Samples from two groups of patients were studied. Patient group 1 included samples from 167 patients that were sent to the clinical microbiological laboratory at the Linköping University Hospital, for bacterial culture because of a suspected bacterial infection in the CNS. The patients in this group had symptoms ranging from low-grade fever with or without increased white blood cells (WBC) in blood or CSF, to acute onset of decreased consciousness, confusion and sepsis. These samples were collected consecutively between January and September 2008. Patient group 2 consisted of 206 patients, who\'s CSF, collected consecutively from January to March and June to July 2007, had been previously analyzed serologically for neuroborreliosis. Many of these patients had diffuse symptoms such as persistent or intermittent headaches; others had a history or symptoms that can be indicative of neuroborreliosis. Four patients out of the 206 (2%) in this group were diagnosed with neuroborreliosis using the IDEIA™ Lyme Neuroborreliosis EIA kit (Oxoid Ltd, Ely UK).

###### 

Sample population of patients

                    Age   Gender distribution   Total                
  ----------------- ----- --------------------- --------- ---------- -----
  Patient group 1   55    0-86                  79 (47)   88 (53)    167
  Patient group 2   49    3-84                  92 (45)   114 (55)   206

Patient group 1 consisted of samples that were sent for bacterial culture because of a suspected bacterial infection in the CNS. Patient group 2 consisted of samples that had been previously analyzed for neuroborreliosis.

Viral nucleic acid extraction
-----------------------------

Total nucleic acid was extracted from 200 μl CSF using MagAttract Virus Mini M48 kit (Qiagen, Solna, Sweden) according to manufacturer\'s instructions and eluted in 75 μl. All samples were frozen after extraction and after MDA-treatment, when performed.

MDA
---

GenomiPhi V2 DNA Amplification kit (GenomiPhi, GE Healthcare, Stockholm, Sweden) was used according to manufacturer\'s instructions on 76 samples, with modification for using 10 μl of DNA extract without sample buffer to maximize initial DNA content. The amplification capacity of MDA for each virus was evaluated by mixing positive herpesvirus DNA controls (Vircell, Santa Fé, Spain) in nuclease-free water or CSF at various concentrations. Real-time PCR results were compared for samples with and without MDA treatment. For this evaluation GenomiPhi was used with either 5 μl template mixed in 5 μl sample buffer, or with 10 μl template without sample buffer. REPLI-g Mini kit (Qiagen) was also used for this evaluation according to the manufacturers\' recommendations with 5 μl template.

Real-time PCR
-------------

Real-time PCR reactions were performed on Rotor-Gene (Corbette Life Science, Sydney, Australia). Extracted samples with and without MDA treatment were thawed and analyzed in parallel. HSV-1 and HSV-2 were analyzed with 1X QuantiTect SYBR Green Master Mix (Qiagen), 5 μl template in a final volume of 25 μl. PCR for detection of Varicella zoster virus (VZV) followed the same protocol as HSV-1 and HSV-2, but using 1X QuantiFast Probe Master Mix (Qiagen). Sample results were analyzed for cycle threshold values and melting curve analysis for HSV-1 and HSV-2. Commercial kits Artus EBV RG PCR kit V1 (Qiagen) and Artus CMV RG PCR kit V1 (Qiagen) were used according to the manufacturer\'s instructions. Enterovirus was detected with RNA UltraSense™ One-Step Quantitative RT-PCR System (Invitrogen, Paisly, United Kingdom) according to manufacturer\'s instructions, with 1X RNA UltraSense™ Reaction mix, 3 mM MgSO~4~, 1.25 μl UltraSense™Enzyme mix and 10 μl template to a final volume of 25 μl. Primers and probes for detection are shown in Table [2](#T2){ref-type="table"}. In Patient group 1, real-time PCR analysis included 167 samples for Human herpes virus (HHV) 1 to 5 and samples from 93 patients for enterovirus. In Patient group 2, corresponding PCR analysis included 206 samples for HHV 1 to 4, 171 samples for cytomegalovirus (CMV) and samples from 110 patients for enterovirus.

###### 

Primers and probes for HSV-1, HSV-2, VZV and enterovirus

  Virus         Primer or probe   Sequence (5\'-3\')           Primer/probe concentration
  ------------- ----------------- ---------------------------- ----------------------------
  HSV-1^1^      Forward           CCATACCGACCACACCGACGA        400 nM
                Reverse           CATACCGGAACGCACCACAC         400 nM
  HSV-2^1^      Forward           TCAGCCCATCCTCCTTCGGC         400 nM
                Reverse           GCGCGGTCCCAGATCGG            400 nM
  VZV           Forward           TGCAGGGCATGGCTCAGT           400 nM
                Reverse           CCCAAGAACCACATGTCCAAC        400 nM
                Probe             TCCAGGGACTTGGGACC            200 nM
  Enterovirus   Forward           CCTGAATGCGGCTAATCCYAAC^2^    400 nM
                Reverse           CRATTGTCACCATAAGCAGCCA^3^    900 nM
                Probe             CCCAAAGTAGTCGGTTCCGCCACAGA   150 nM

^1^Primers for HSV-1 and modified primers for HSV-2 from Franzén-Röhl 2008^7^.

^2^Degenerate primer, Y = T or C

^3^Degenerate primer, R = G or A.

Results
=======

Real-time PCR
-------------

Out of totally 167 patients in Patient group 1, with suspected bacterial CNS infection, viral NA was detected in the CSF of 15 patients using real-time PCR (Table [3](#T3){ref-type="table"}). Epstin-Barr virus (EBV) was the most common viral DNA detected (9 patients). As described in Table [4](#T4){ref-type="table"}, CNS symptoms was due to non-infectious causes in several cases; subarachnoid or cerebellar hemorrhage (n = 5), tumors (n = 3) or was explained by bacterial infection (n = 4) or shunt dysfunction (n = 2). In two cases, EBV DNA was detected together with HSV-1 or VZV DNA. Among the 206 patients with possible neuroborreliosis, (Patient group 2), viral NA (EBV) was detected in two cases.

###### 

Real-time PCR detected viral DNA in the two patient groups

  Virus                     Patient group 1 (167 tot)   Patient group 2 (206 tot)       
  ------------------------- --------------------------- --------------------------- --- ----
  HSV-1                     2                           1%                          0   0%
  HSV-2                     1                           0.6%                        0   0%
  VZV                       1                           0.6%                        0   0%
  EBV                       7                           4%                          2   1%
  CMV                       1                           0.6%                        0   0%
  EV                        1                           0.6%                        0   0%
  HSV-2 + EBV               1                           0.6%                        0   0%
  VZV + EBV                 1                           0.6%                        0   0%
                                                                                        
  Total positive patients   15                          9%                          2   1%

###### 

Clinical and laboratory finding in patients positive for virus in CSF

                                                                                                         Symptoms     blood     CSF                                                                                           
  --------- --------- --------- ------------- --------------------- ------------------------------------ ------------ --------- --------- --------- ---------- ---------- --------------- ----------------------------------- -----
  **Pat**   **Age**   **Sex**   **Results**   **Admission cause**   **Enceph**                           **Mening**   **WBC**   **CRP**   **WBC**   **Poly**   **Mono**   **Diagnosis**   **AVT**                             
                                                                                                                                                                                                                              
  1         77        M                       EBV                   acute onset, reduced conciousness    No           No        11        62        5          2          3               SAH, bacterial infection            
                                                                                                                                                                                                                              
  2         64        F         VZV           EBV                   fever, decreased consciousness       No           No        9         45        427        170        257             Brain tumor                         
                                                                                                                                                                                                                              
  3         53        M         HSV2          EBV                   fever, decreased consciousness       No           Yes       11        109       135        27         108             Brain hemorrhage, meningitis        
                                                                                                                                                                                                                              
  4         53        M         HSV1                                headache, personality change         Yes          No        8         \< 10     0.5        0.4        0.1             Hydrocephalus/encephalitis          
                                                                                                                                                                                                                              
  5         82        M                       CMV                   fever, post op cerebi                No           No        17        63        21         5          16              Meningioma, infection               
                                                                                                                                                                                                                              
  6         86        F                       EV                    fever, decreased consciousness       Yes          Yes       10        140       1.4        0          1.4             Herpes zoster, bacteremia           yes
                                                                                                                                                                                                                              
  7         61        F                       EBV                   post op double vision, CSF leakage   No           No        10        \< 10     1315       515        800             Meningioma, post-op meningitis      
                                                                                                                                                                                                                              
  8         70        F         HSV2                                sudden headache                      No           Yes       6         11        103        18.6       84              HSV2 meningitis                     
                                                                                                                                                                                                                              
  9         58        M         HSV1                                acute confusion, dysphasia           Yes          No        16        \< 10     27         0.6        26              HSV1 encephalitis                   yes
                                                                                                                                                                                                                              
  10        52        F                       EBV                   dizziness, vomiting, headache        No           No        18        89        104        n.d        n.d.            SAH                                 
                                                                                                                                                                                                                              
  11        56        M         VZV                                 Rash, decreased consciousness        No           Yes       6         111       26         0          26              varicella meningitis                yes
                                                                                                                                                                                                                              
  12        65        M                       EBV                   Fever, post op cerebri               No           No        11        32        150        2          148             Spinal metastasis, *S. aureus*inf   
                                                                                                                                                                                                                              
  13        65        M                       EBV                   ventricular shunt dysfunction        No           No        5.5       \< 10     109        3          106             ventricular shunt dysfunction       
                                                                                                                                                                                                                              
  14        63        M                       EBV                   fever post-op                        No           No        9         \< 10     1.7        0.1        1.6             SAH                                 
                                                                                                                                                                                                                              
  15        54        F                       EBV                   acute headache                       No           No        16        98        96         n.d.       n.d             SAH, pneumonia                      
                                                                                                                                                                                                                              
  16        60        F                       EBV                   dizziness, arm weakness              No           No        6         \< 10     1          0.2        0.6             cerebrovascular disease             
                                                                                                                                                                                                                              
  17        40        F                       EBV                   double vision, dysphasia, headache   Yes          No        14        \< 10     514        10         504             Borrelia                            yes

SAH: subarachnoidal hemorrhage, Enceph: encephalitis, Mening: meningitis, WBC: white blood cells, CSF: cerebrospinal fluid, CRP: C-reactive protein, Poly: polymorphonuclear cells, Mono: mononuclear cells, AVT: antiviral treatment, n.d.: not determined.

MDA
---

Five samples (one each of HSV-1, HSV-2 and CMV, and two EBV) in which viral DNA was detected by PCR (without MDA) were negative by PCR after MDA. Conversely, one sample from Patient group 1 was positive for HHV DNA only after MDA amplification. This sample showed a very weakly positive signal after MDA treatment, suggesting that the amount of viral NA was close to the assay cut off. EBV was detected in two samples both with and without MDA. These two EBV samples displayed higher Ct values for MDA products, suggesting that MDA did not increase the sensitivity for viral DNA. Since MDA did not increase the sensitivity for detecting HHV it was not performed on more than 76 samples.

A reason why MDA-treatment did not increase sensitivity could be that viral DNA is scarce in CSF compared to the amount of human genomic DNA. Therefore we studied the amplification of viral DNA from infected cell cultures. MDA-treated viral DNA diluted in CSF compared to water showed a poorer amplification for viral DNA, particularly at lower concentrations. These results suggest that MDA negatively discriminates viral DNA in presence of human nucleic acid.

Discussion
==========

In this study we found no support for low-grade or intermittent shedding of latent HHV DNA into the CSF in patients without signs of viral CNS infection. The identification of viral NA in samples sent for bacterial culture is interesting and probably reflects that clinical symptoms are not easily categorised as due to bacterial or viral infection in the CNS. Probably, bacterial culture is requested also in the absence of typical meningitis in patients who are old, have a complex medical history or are immunologically suppressed.

Viral NA was detected in 15 samples (8%) sent for bacterial culture on the suspicion of possible bacterial CNS infection (Patient group 1). HSV-1, HSV-2 or VZV DNA was detected in 6 of these cases. Five of these had a clinical presentation compatible with viral meningitis or encephalitis, while such symptoms were absent in one case (Pat no 2). CMV was detected in one patient, but the clinical picture did not support CMV-caused infection. EBV DNA was detected in 9 patients in Group 1, but only few of them had signs of CNS infection and none had symptoms typical for EBV infection (fever, mononucleosis). It has been described that EBV can cause CNS infections by itself, particularly in immunocompromised patients \[[@B15]-[@B18]\] but EBV DNA has also been detected in CSF and synnovial fluid from patients without likely EBV-infection \[[@B8],[@B9],[@B19]\]. Our results support the latter, but it is important to note that our material primarily is from patients without suspected viral infection.

It is to our knowledge not yet known if EBV DNA detected in the CSF origins from the CNS itself or from infiltrative white blood cells due to inflammation. The explanation that EBV is borne by WBCs may be favoured, since we could only detect EBV in patients with other traumatic and/or inflammatory processes in the CNS, see Table [4](#T4){ref-type="table"}.

Viral NA (EBV) was detected in only two of the samples in Patient group 2 (0.5%). One patient had a clinical presentation characteristic for neuroborreliosis, and did not have fever or other signs of EBV infection. The other patient had no signs of infection but suffered from cerebrovascular disease. The more rare detection of viral NA in Patient group 2 was not surprising because the majority of these samples were collected from patients with diffuse symptoms of long duration, drawn because the clinician wanted to exclude the possibility of neuroborreliosis.

Enterovirus infections in the CNS are common and may present as meningitis in a manner that may mimic bacterial infection. Still, enterovirus RNA was detected in only one positive sample in Patient group 1 and the sample was very weakly reactive. The patient did not have typical symptoms for enterovirus infection, nor increased white blood cells in the CSF.

The absence of detectable viral NA suggests that viruses were not present in the CSF or that our methods for detection are still not sensitive enough. Most real-time PCR methods detect 1 to 10 viral particles/PCR reaction, but the concentration of these viruses in CSF during subclinical infection might be very low. A higher sensitivity could probably be achieved by using larger CSF extraction volumes (5-20 ml), but in general this is not practically possible.

In our study, MDA amplified viral DNA satisfactorily in the absence of other nucleic acids, but showed poor amplification capacity for viral detection in CSF and did not overall increase the sensitivity for HHV detection with our methodology. A possible explanation why viral DNA was not amplified could be the viruses\' shorter genome, the nature of viral DNA, or as reported in a study of *H. pylori*DNA, impact from excess of human genomic DNA \[[@B20]\]. The reportedly good performance of MDA amplification for human papilloma virus (HPV) and human immunodeficiency virus (HIV) may be explained by the fact that in these cases, viral DNA can be integrated into the human genome \[[@B13],[@B21]\]. This suggests that HHV DNA, which is not inserted into the human genome, is discriminated by this method.

Conclusions
===========

In summary, our results show that viral infection, in particular HSV and VZV, should be suspected in patients with putative bacterial CNS infection. Conversly, patients presenting clinical symptoms suggesting HSV-1 encephalitis may have bacterial cause *e.g*. listerial infections \[[@B22],[@B23]\]. The findings also indicate that MDA does not serve to enhance the performance of real-time PCR, which alone is a both highly sensitive and specific method for detecting viral CNS infections.
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